News

Carving out CGTs for payment systems involving government intervention may be an answer

DuPont/Cold Chain Technologies in thermal blankets; va-Q-tec in shipment tracking; big bucks for SkyCell

UPS and CVS Pharmacy collaborate for direct-to-patient delivery; but check out Matternet, UPS’ drone partner

Cellular and genetic therapies (CGTs) are a minor part of commercial business, but a growing part of research activity

Kit Check data show value of track-and-trace technology, especially during the Covid-19 pandemic

Revenue leakage in contracting and sales execution affects 95% of respondents

Acquisition of Cumberland Life Sciences boosts its client base and range of services

Service providers are resetting their business practices to cope with the pandemic

Hub service providers look to telehealth to expand patient connectivity

Production quotas for controlled substances are being raised by 15%

Now a Danaher Corp. asset, the former GE Healthcare Life Sciences business has been reshuffled

Newly initiated trials may prove value—but even then, supplies may be limited, and hoarding is already occurring

When a physician prescribes or treats a patient with your specialty drug, the stakes are high for everyone. Patient access is evolving to improve the patient and physician journey with specialty therapies

For sessions with co-workers or clients, consider these recommendations

As of March 26, 71 treatments and 47 vaccines are in development

US list-price sales reached $510 billion in 2019

Passenger-based carriers are repurposing their flights

Healthcare Ready pools industry efforts

DEA-registered practitioners can prescribe without an in-person interview

Guidance enables these workers to continue reporting to work

CoverMyMeds report gives evidence of ongoing difficulties in patient support

Copenhagen, Denmark tops Boyd Co.’s list with the highest annual operating costs

But: the growth number of companies is exceeding the growth of trials

The big question is how well will the system respond to spikes in demand, and lack of product

PCMA study disputes its members’ harm to brick-and-mortar businesses

Dramatic growth tracks the flood of new specialty pharmaceuticals entering the market